Advertisement

Topics

Eiger Announces First Patient Dosed in Phase 2 Study of Pegylated Interferon Lambda in Hepatitis D Virus (HDV) Infection

04:06 EDT 19 Oct 2016 | PR Newswire
This article has expired, however you can still download the PDF.
Preview:
PALO ALTO, Calif., Oct. 19, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that the first patient was dosed in the Phase 2 LIMT HD...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Eiger Announces First Patient Dosed in Phase 2 Study of Pegylated Interferon Lambda in Hepatitis D Virus (HDV) Infection"

Quick Search
Advertisement
 

Relevant Topic

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...